CRP and type 2 diabetes mellitus: Exendin-based GLP-1 exenatide has been shown to reduce weight and glycosylated hemoglobin (HbA1c), systolic blood pressure, triglycerides, and high-sensitivity C-reactive protein (CRP) (hsCRP) in obese patients with type 2 diabetes.